¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cross reactive antibody"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody removal
    Ç×üÁ¦°Å
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody valence
    Ç×ü°áÇÕ°¡
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î¼º
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • maltese cross
    ¸»Å×½º½ÊÀÚÇü
  • testosterone cross-reactivity
    ³²¼ºÈ£¸£¸ó±³Â÷¹ÝÀÀ¼º
  • direct cross matching
    Á÷Á¢±³Â÷½ÃÇè
  • innervated cross finger flap
    ½Å°æÁö¹è¼Õ°¡¶ô±³Â÷ÇÇÆÇ
  • plasma cross matching
    (¢¡cross matching) Ç÷Àå±³Â÷½ÃÇè
  • nerve cross over
    ½Å°æ±³Â÷¼ú
  • antibody
    Ç×ü
  • anaphylactic antibody
    ¾Æ³ªÇʶô½Ã½ºÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody removal
    Ç×üÁ¦°Å
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody feedback mechanism
    Ç×üµÇ¸ÔÀ̱â±âÀü.
  • antibody formation
    Ç×üÇü¼º(ù÷ô÷û¡à÷).
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody half-life
    Ç×ü¹Ý°¨±â(ù÷ô÷ÚâÊïÑ¢).
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody production
    Ç×ü»ý»ê(¡­ßæß§).
  • antibody removal
    Ç×üÁ¦°Å
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • antibody screening cells
    Ç×ü¼±º°Ç÷±¸
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody structure
    Ç×ü±¸Á¶(¡­Ï°ðã).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cross reactivation
    ±³Â÷Ȱ¼ºÈ¸º¹.[»ýÈ­]±³Â÷Ȱ¼ºÈ­(¡­üÀàõûù).
  • cross reactivation
    ±³Â÷Ȱ¼ºÈ¸º¹.[»ýÈ­]±³Â÷Ȱ¼ºÈ­(¡­üÀàõûù).
  • cross reactivation
    ±³Â÷ÀçȰ¼ºÈ­
  • cross reactivity
    ±³Â÷¹ÝÀÀ¼º.
  • cross reactivity
    ±³Â÷ ¹ÝÀÀ
  • cross relaxation
    ±³Â÷ ÀÌ¿Ï
  • cross resistance
    ±³Â÷ÀúÇ×.
  • cross resistance
    ±³Â÷ÀúÇ×.
  • cross resistance
    ±³Â÷³»¼º
  • cross section radiography
    ´ÜÃþÃÔ¿µ¼ú
  • cross sectional echocardiogram
    ´ÜÃþ½ÉÃÊÀ½ÆÄµµ.
  • cross sectional echocardiography
    ´ÜÃþ½ÉÃÊÀ½ÆÄ°Ë»ç.¹æ»ç¼±´ÜÃþ½É¿¡ÄÚ °Ë»ç.
  • cross sectional echocardiography
    ´ÜÃþ½ÉÃÊÀ½ÆÄ°Ë»ç
  • cross sensitization
    ±³Â÷°¨°¢(Îßó©ÊïÊÆ).
  • cross sensitization
    ±³Â÷ °¨ÀÛ(Îßó© ÊïíÂ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • heterocytotropic antibody
    ÀÌÁ¾Ä£È­¼º Ç×ü(ì¶ðúöÑûúàõù÷ô÷)
  • heterophile antibody
    ÀÌÈ£¼º Ç×ü(ì¶û¿àõù÷ô÷)
  • heterospecific antibody
    ÀÌÁ¾Æ¯ÀÌ Ç×ü(ì¶ðú÷åì¶ù÷ô÷)
  • homocytotropic antibody
    µ¿Á¾¼¼Æ÷ģȭ¼º Ç×ü(ÔÒðúá¬øàöÑûúàõù÷ô÷)
  • homospecific antibody
    "µ¿(ÔÒ)(Á¾,ðú) ƯÀÌÇ×ü(÷åì¶ù÷ô÷)"
  • hybrid antibody
    Æ¢±â Ç×ü(ù÷ô÷)
  • idiotypic antibody
    °³Ã¼Æ¯ÀÌÇü(ËÁô÷÷åì¶úþù÷ô÷)
  • immune antibody
    ¸é¿ª Ç×ü(Øóæ¹ù÷ô÷)
  • incomplete antibody
    ºÒ¿ÏÀü Ç×ü(ÝÕèÇîïù÷ô÷)
  • indirect fluoresccnt antibody technique
    °£Á¢ Çü±¤Ç×ü¼ú(ÊàïÈû«ÎÃù÷ô÷âú)
  • isophile antibody
    È£µ¿Á¾ Ç×ü(û¿ÔÒðúù÷ô÷)
  • low-order antibody
    ÀúÂ÷Ç×ü(î¸ó­ù÷ô÷)
  • multivalent antibody
    ´Ù°¡Ç×ü(Òýʤù÷ô÷)
  • natural antibody
    ÀÚ¿¬Ç×ü(í»æÔù÷ô÷)
  • nonagglutinating antibody
    ºñÀÀÁýÇ×ü(Þªëêó¢ù÷ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ReA Reactive Arthritis
BRM biological response modifier; biuret reactive material
CRPA C-reactive protein antiserum
IRIg insulin-reactive immunoglobulin
PERRLA pupils equal, round, and reactive to light and accommodation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
MCA minimum cross-sectional area
TBARS 2-Thiobarbituric acid-reactive substances
TBARS 2-thiobarbituric reactive substances
CRP C - reactive protein
IRI Immuno Reactive Insulin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • enzyme labeled antibody
    È¿¼Ò Ç¥Áö Ç×ü
  • enzyme-labelled antibody
    È¿¼Ò Ç¥Áö Ç×ü
  • fluorescein-labelled antibody
    Çü±¤ Ç¥Áö Ç×ü
  • fluorescent antibody stain
    Çü±¤ Ç×ü ¿°»ö
  • fluorescent antinuclear antibody test
    Çü±¤ Ç×ÇÙ Ç×ü ½ÃÇè
  • fluorescent treponemal antibody test
    ¸Åµ¶ Æ®·¹Æ÷³×¸¶ Çü±¤ Ç×ü °Ë»ç, Çü±¤¼º ¸Åµ¶±Õ Ç×ü ½ÃÇè¹ý
  • hemolytic antibody
    ¿ëÇ÷ Ç×ü
  • HIV antibody
    HIV Ç×ü
  • humoral antibody
    ¾×¼º Ç×ü
    ü¾×¼º ¸é¿ªÀ» ´ã´çÇÏ´Â ¸é¿ª ±Û·ÎºÒ¸°. ³× °³ÀÇ
  • humoral antibody
    ¾×¼º Ç×ü, ü¾×¼º Ç×ü, ü¾× Ç×ü
  • humoral cytotoxic antibody
    ü¾×¼º ¼¼Æ÷ µ¶¼º Ç×ü
  • immunofluorecent antibody test
    ¸é¿ª Çü±¤ Ç×ü °Ë»ç¹ý
  • intrinsic factor antibody
    ³»Àμº ÀÎÀÚ Ç×ü
  • Jo-1 antibody
    Jo-1 Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
antibody-forming cell <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies.
(09 Feb 1998)
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
anti-idiotype antibody <immunology> An antibody directed against the antigen specific part of the sequence of an antibody or T-cell receptor and thus recognise the binding sites of other antibodies.
In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.
(13 Nov 1997)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
antinuclear antibody <immunology> Antinuclear antibody is an antibody that react against components of the cell nucleus such as DNA, RNA, histone or non-histone proteins.
These antibodies are present in a variety of immunologic or autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, scleroderma, Sjogren's syndrome, rheumatoid arthritis, polymyositis, dermatomyositis and in persons taking hydralazine, procainamide or isoniazid.
A serologic measurement for antinuclear antibodies can aid in the diagnosis of unexplained arthritis, rashes or chest pains.
Acronym: ANA
(12 Jan 1998)
anti-P antibody <haematology, investigation> A serologic blood test used to detect the Donath-landsteiner antibody in serum.
This test is performed in cases of suspected paroxysmal cold haemoglobinuria. A normal result is indicated by an absence of antibodies. The antibody is directed toward the P-antigen complex which is located on the surface of red blood cells. In some way, cold temperatures trigger the antibody to bind to this site.
(13 Jan 1998)
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
antiphospholipid antibody <immunology, syndrome> An uncommon disorder that is characterised by hypercoagulability due to the presence of antibodies against phospholipids.
These patients exhibit a tendency for recurrent and life-threatening thrombosis and embolic events (for example stroke). Individuals with antiphospholipid syndrome also have an increased tendency toward deep venous thrombosis, myocardial infarction and spontaneous abortions in females.
Antiphospholipid syndrome may be seen by itself or in association with other autoimmune illnesses (for example lupus) or with some infections.
Treatment includes long-term heparin and warfarin.
(13 Jan 1998)
antiphospholipid antibody syndrome <syndrome> An immune disorder characterised by the presence of abnormal antibodies in the blood associated with certain medical conditions including abnormal blood clotting, migraine headaches, premature miscarriage, and low blood platelet counts (thrombocytopenia).
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cross-license
    (´Ù¸¥ ȸ»ç¿Í)»óÈ£ ƯÇã »ç¿ë °è¾àÀ» ¸Î´Ù
  • cross-link
    ±³Â÷ °áÇÕ(¿øÀÚ±º);±³Â÷ °áÇÕ½ÃŰ´Ù(ÇÏ´Ù)
  • cross-match
    (¼öÇ÷ Àü¿¡)±³Â÷(ÀûÇÕ)½ÃÇèÀ» ÇÏ´Ù
  • cross-modal
  • cross-ownership
    (½Å¹®»ç¿Í ¶óµð¿À.ÅÚ·¹ºñÀü ȸ»çÀÇ)°øµ¿¼ÒÀ¯
  • cross-polinate
    ÀÌÈ­¼öºÐ ½ÃŰ´Ù
  • cross-polination
    ÀÌÈ­ ¼öºÐ
  • cross-purpose
    ¹Ý´ë ¸ñÀû;(ÀÇÇâÀÇ) »óÄ¡;µ¿¹®¼­´ä½Ä ¹®´ä³îÀÌ
  • cross-question
    ¹Ý´ë½É¹®ÇÏ´Ù(crossexamine);¹Ý¹®;Èú¹®
  • cross-refer
    ÀüÈÄ(»óÈ£)ÂüÁ¶ÇÏ´Ù;(µ¶ÀÚ¿¡°Ô)»óÈ£ ÂüÁ¶½ÃŰ´Ù
  • cross-reference
    (°°Àº üÁßÀÇ)ÀüÈÄ(»óÈ£)ÂüÁ¶;=CROSS-REFER
  • cross-sectional
    Ⱦ´Ü¸éÀÇ;(Àüü¸¦ ´ëÇ¥ÇÏ´Â)´Ü¸éÀÇ
  • cross-sectional X-ray
    ´ÜÃþ¸é X¼±
  • cross-staff
    Á÷°¢±â
  • cross-stitch
    (XÀÚ²ÃÀÇ)½ÊÀÚ¶ß±â(·Î ÇÏ´Ù)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á